Loading…
COCP
Cocrystal Pharma, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 19188J409
$1.10-3.51%Price as of Aug 29, 18:34 UTC · updated once a day, after the close
Key metrics
- Market cap
- $21.19M
- P/E
- —
- Forward P/E
- —
- P/B
- 14.5x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.75
- ROE
- -311.68%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 1.43
- 52-week high
- $2.67
- 52-week low
- $0.76
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -89.0% over 5Y.
today you would have $92.86▼ -90.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 14 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $0.98 | $2.02 | $1.72 | $1.95 | $7.80 | $16.32 | $6.00 | $43.20 | $72.00 | $140.40 | $320.40 | $151.20 | $230.40 | $1,170.00 | |
| P/S | — | — | — | — | — |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| LFWDLifeward Ltd. | $7.46 | — | 3.3x | — | -225.65% | $21.13M |
| CTSOCytosorbents Corp | $0.34 | — | — | — | -336.21% | $21.09M |
| LGVNLongeveron Inc. | $6.72 | — | 20.5x | — | -203.61% | $21.42M |
| BNGOBionano Genomics, Inc. | $1.82 |
About the company
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was headquartered in Bothell, Washington.
- 10
- Bothell, United States
Company description provided by Yahoo Finance.